For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectively Rare Disease business delivered exceptional growth with full year 2025 Purified Cortrophin® Gel net revenues of $347.8 million, up 76% year-over-year, and ILUVIEN and YUTIQ net revenues of $74.9 million, based on preliminary, unaudited results Provides full year 2026 financial guidance, which includes: Total net revenues of $1,055 million to $1,115 million Cortrophin Gel net revenues of $540 million to $575 million Adjusted non-GAAP EBITDA of $275 million to $290 million Rare Disease business to represent approximately 60% of total net revenues Announces ~90-person expansion of Rare Disease organization to capture unique opportunity for Cortrophin Gel in acute gouty arthritis flares; expected to deploy in mid-2026 PRINCETON, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced preliminary select financial results for full year 2025, provided full year 2026 financial guidance, and outlined its strategic priorities for continued growth.
